In particular, no express or implied licenses or other rights are provided to use the MATERIAL, MODIFICATIONS, or any related patents of the PROVIDER for COMMERCIAL PURPOSES. To use the UBMTA, complete the implementing letter the sharing of these tools will impact further, downstream faculty build spin-out Some examples include: subclones of unmodified cell lines, purified or fractionated subsets of the ORIGINAL MATERIAL, proteins expressed by DNA/RNA supplied by the PROVIDER, or monoclonal antibodies secreted by a hybridoma cell line. should always keep a record of MTAs related to their research and make sure their The review of an incoming MTA ensures the agreement terms don't conflict with rights granted in other agreements associated with the research. Tel: 619-594-5938 The RECIPIENT and the RECIPIENT SCIENTIST agree to refer to the PROVIDER any request for the MATERIAL from anyone other than those persons working under the RECIPIENT SCIENTIST's direct supervision. The UBMTA (Uniform Biological Materials Transfer Agreement) can be used only with non-profit organizations which have signed a Master Agreement with NIH. The SDSU Technology Transfer Office negotiates the terms of the MTAs and the Intellectual Property (IP) aspects of using or if the materials had been shared through an MTA. The RECIPIENT agrees to use the MATERIAL in compliance with all applicable statutes and regulations, including Public Health Service and National Institutes of Health regulations and guidelines such as, for example, those relating to research involving the use of animals or recombinant DNA. to non-profit entities, the Simple Agreement for Transfer of Non-proprietary Biological 10. MTAs (incoming and outgoing) must undergo a compliance review to ensure that the appropriate compliance protocols are in place for: Some repositories require registrations and some require MTAs, and some require both. MTAs are important documents for technology transfer; they can be both free as well the  Uniform Biological MaterialTransfer Agreement (UBMTA) as published in the Federal Register on March 8, 1995 and has placed on file with 5250 Campanile Drive The MTA defines the rights of the provider and the recipient with respect to the materials and any derivatives. NIH policy from 1999 directs that research reagents generated through the use of public funds be transferred amongst researchers either with “no formal agreement, a cover letter, the Simple Letter Agreement of the Uniform Biological Materials Transfer Agreement (UBMTA), or … The name and address of this party will be specified in an implementing letter. 6. signatories to the UBMTA may be completed by using a brief UBMTA Implementing Letter which identifies the material and the parties and confirms that the transfer is being Systems, Research 4. Conflict of Interest Certification in Research, Uniform Biological Material Transfer Agreement (UBMTA) Master Agreement, Research Contract Agreement Documents and Forms, Sexual Misconduct Reporting and Awareness, Electronic & Information Resources Accessibility, Discrimination and Sexual Misconduct Reporting and Awareness, Log the agreement for tracking purposes and route to the appropriate contracting officer and compliance Offices, Compliance review and approve for Human Subjects, Animals, Conflicts of Interest, Office of Research Integrity and Oversight (RIO), Compliance review and approve for biohazard Materials, Environmental Health and Life Safety (EHLS), Review and negotiate the terms and condition of the agreement as needed. 2. may be useful to develop another line of questioning or confirm findings at another among scientists. ORIGINAL MATERIAL: The description of the material being transferred will be specified in an implementing letter. Fields, Pathways It is recognized by the RECIPIENT that such COMMERCIAL PURPOSES may require a commercial license from the PROVIDER and the PROVIDER has no obligation to grant a commercial license to its ownership interest in the MATERIAL incorporated in the MODIFICATIONS. What do I need to know about the customs and importation process for my country? If you run into any problems registering, depositing, or ordering please contact us at [email protected] copy of the UBMTA. In 1995, the NIH published the first and only widely accepted model agreements for transfers of materials, the NIH Simple Letter Agreement for the Transfer of Materials (SLA) and the Uniform Biological Material Transfer Agreement (UBMTA), along with guidance for the transfers of research tools. The RECIPIENT retains ownership of: (a) MODIFICATIONS (except that, the PROVIDER retains ownership rights to the MATERIAL included therein), and (b) those substances created through the use of the MATERIAL or MODIFICATIONS, but which are not PROGENY, UNMODIFIED DERIVATIVES or MODIFICATIONS (i.e., do not contain the ORIGINAL MATERIAL, PROGENY, UNMODIFIED DERIVATIVES). 2. Whether the material is incoming or outgoing, agreements of this type are negotiated by the Division of Research. 13. d) will not be transferred to anyone else within the RECIPIENT organization without the prior written consent of the PROVIDER. For materials that may be patented or for which more protection is desired, the Uniform Biological Material Transfer Agreement (UBMTA) can be used. UNMODIFIED DERIVATIVES: Substances created by the RECIPIENT which constitute an unmodified functional subunit or product expressed by the ORIGINAL MATERIAL. iii) in the event the PROVIDER terminates this Agreement under 13( c) other than for breach of this Agreement or for cause such as an imminent health risk or patent infringement, the PROVIDER will defer the effective date of termination for a period of up to one year, upon request from the RECIPIENT, to permit completion of research in progress. The MTA defines the rights of the provider and the recipient with respect to the materials and any derivatives. RECIPIENT SCIENTIST: The name and address of this party will be specified in an implementing letter. restrictions and reporting requirements. Except as provided in this Agreement, no express or implied licenses or other rights are provided to the RECIPIENT under any patents, patent applications, trade secrets or other proprietary rights of the PROVIDER, including any altered forms of the MATERIAL made by the PROVIDER.